InMed Pharmaceuticals (INM) EBITDA Margin (2021 - 2025)
InMed Pharmaceuticals (INM) reported EBITDA Margin of 256.36% for Q4 2025, down 5470.0% on a YoY basis from 4.77% in Q4 2024, and down 57.72% quarter-over-quarter from 162.54% in Q3 2025.
InMed Pharmaceuticals (INM) EBITDA Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported EBITDA Margin for 5 years, with the latest figure at 256.36% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 5470.0% year-over-year to 256.36%; the trailing twelve-month figure through Dec 2025 stood at 183.62% (down 2174.0% YoY), and the FY2025 full-year result was 159.76%, up 1747.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 256.36%, down from 162.54% in the prior quarter.
- The five-year high for EBITDA Margin was 20.43% in Q2 2023, with the low at 1615.6% in Q4 2021.
- Historically, EBITDA Margin has averaged 462.24% across 5 years, with a median of 193.24% in 2023.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 150844 bps — and 2024, when it sank 13769 bps.
- InMed Pharmaceuticals' EBITDA Margin stood at 1615.6% in 2021, then surged by 72 bps to 447.25% in 2022, then surged by 71 bps to 131.49% in 2023, then tumbled by 53 bps to 201.65% in 2024, then dropped by 27 bps to 256.36% in 2025.
- The last three EBITDA Margin figures came in at 256.36% (Q4 2025), 162.54% (Q3 2025), and 188.23% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | InMed Pharmaceuticals | 6.04 Mn | 796,124.14 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -256.36% |
| Sep 30, 2025 | -162.54% |
| Jun 30, 2025 | -188.23% |
| Mar 31, 2025 | -150.27% |
| Dec 31, 2024 | -201.65% |
| Sep 30, 2024 | -136.12% |
| Jun 30, 2024 | -158.12% |
| Mar 31, 2024 | -156.07% |
| Dec 31, 2023 | -131.49% |
| Sep 30, 2023 | -294.84% |
| Jun 30, 2023 | -20.43% |
| Mar 31, 2023 | -193.24% |
| Dec 31, 2022 | -447.25% |
| Sep 30, 2022 | -1,094.24% |
| Jun 30, 2022 | -1,528.88% |
| Mar 31, 2022 | -1,122.69% |
| Dec 31, 2021 | -1,615.60% |